Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.
- DOI
- 10.1002/art.70280
- Published
- 2026-07-20
- Container
- Arthritis Rheumatol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/art.70280,
title = {Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.},
author = {Mease PJ and Chandran V and Armstrong AW and Blanco R and Ogdie A and Siegel EL and Gottlieb AB and Zeng X and Thaçi D and Kishimoto M and Schulze-Koops H and Kivitz A and Dokoupilová E and Morita A and Ruderman EM and Plewinski M and Wang K and Sardinas C and Vritzali E and Vaile J and Deodhar A.},
year = {2026},
journal = {Arthritis Rheumatol},
doi = {10.1002/art.70280},
url = {https://doi.org/10.1002/art.70280}
}RIS
TY - JOUR TI - Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. AU - Mease PJ AU - Chandran V AU - Armstrong AW AU - Blanco R AU - Ogdie A AU - Siegel EL AU - Gottlieb AB AU - Zeng X AU - Thaçi D AU - Kishimoto M AU - Schulze-Koops H AU - Kivitz A AU - Dokoupilová E AU - Morita A AU - Ruderman EM AU - Plewinski M AU - Wang K AU - Sardinas C AU - Vritzali E AU - Vaile J AU - Deodhar A. PY - 2026 JO - Arthritis Rheumatol DO - 10.1002/art.70280 UR - https://doi.org/10.1002/art.70280 ER -
APA
PJ, M., V, C., AW, A., R, B., A, O., EL, S., AB, G., X, Z., D, T., M, K., H, S., A, K., E, D., A, M., EM, R., M, P., K, W., C, S., E, V., J, V., & A., D. (2026). Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.. Arthritis Rheumatol. https://doi.org/10.1002/art.70280
Source records
- europe-pmc · retrieved 2026-09-26T23:14:30.003Z